Neurotransmitter depleter tetrabenazine; potential candidate for schizophrenia treatment?

Schizophrenia Research

Volumn 96, Issue 1-3, 2007, Pages 267-268

  Malik, Abid ^a   Balkoski, Victoria ^b  

^a Area Mental Health Center   (United States)

^b ALBANY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROMAZINE; CLOZAPINE; DOPAMINE; DOPAMINE RECEPTOR BLOCKING AGENT; FLUPHENAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; NEUROTRANSMITTER; OLANZAPINE; RESERPINE; SERTINDOLE; TETRABENAZINE;

AGRANULOCYTOSIS; BASAL GANGLION; DEPRESSION; DISTRESS SYNDROME; DOPAMINERGIC SYSTEM; DROWSINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; HUNTINGTON CHOREA; LETTER; LIMBIC SYSTEM; NEGATIVE SYNDROME; PARKINSONISM; PRIORITY JOURNAL; SCHIZOPHRENIA; SYMPTOMATOLOGY; TARDIVE DYSKINESIA; UNSPECIFIED SIDE EFFECT;

ADRENERGIC UPTAKE INHIBITORS; CLINICAL TRIALS AS TOPIC; HUMANS; SCHIZOPHRENIA; TETRABENAZINE;

EID: 34848816453     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2007.07.010     Document Type: Letter

References (12)

1. Ashcroft G.W., MacDougall E.J., and Barker P.A. A comparison of tetrabenazine and chlorpromazine in chronic schizophrenia. J. Ment. Sci. 107 (1961) 287-293
2. Blomqvist A.G., Léger P.T., and Hoch J.S. The cost of schizophrenia: lessons from an international comparison. J. Mental Health Policy Econ. 9 4 (2006) 177-183
3. Bonelli R.M., and Wenning G.K. Pharmacological management of Huntington's disease: an evidence-based review. Curr. Pharm. Des. 12 21 (2006) 2701-2720
4. Burke R.E., Fahn S., Mayeux R., et al. Neuroleptic malignant syndrome caused by dopamine-depleting drugs in a patient with Huntington disease. Neurology 31 8 (1981) 1022-1025
5. Huntington Study Group. Tetrabenazine as anticholera therapy in Huntington disease: a randomized controlled trial. Neurology 66 3 (2006) 366-372
6. Kalian M., Lerner V., and Goldman M. Atypical variants of tardive dyskinesia, treated by a combination of clozapine with propranolol and clozapine with tetrabenazine. J. Nerv. Ment. Dis. 181 10 (1993) 649-651
7. Lieberman J.A., Stroup T.S., McEvoy J.P., et al. Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia. N. Engl. J. Med. 353 12 (2005) 1209-1223
8. Lingjaerde O. Tetrabenazine (Nitoman) in the treatment of psychosis with a discussion on the central mode of action of tetrabenazine and reserpine. Acta Psychiatr. Scand. 39 SUPPL 170 (1963) 1-190
9. Mangalore R., and Knapp M. Cost of schizophrenia in England. J. Mental Health Policy Econ. 10 1 (2007) 23-41
10. McEvoy J.P., Lieberman J.A., Stroup T.S., et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am. J. Psychiatry 163 4 (2006) 600-610
11. Perquin L.N. Treatment with the new antipsychotic sertindole for late-occurring undesirable movement effects. Int. Clin. Psychopharmacol. 20 6 (2005) 335-338
12. Smith M.E. Clinical comparison of tetrabenazine (Ro 1-9569), reserpine and placebo in chronic schizophrenics. Dis Nerv Syst. 21 3 Suppl (1960) 120-123